TeamDrive
RUS
Victor Stankevich

Victor Stankevich

Founding Partner, CEO

Телефоны:

+7 495 545-39-12

Send message

Viktor Stankevich is a Founding Partner of RMI Partners, a venture capital investment company in the area of innovative biopharmaceutical products.

Viktor has extensive experience of establishing and developing major projects in different sectors of the economy. In 2006-2012 Victor held different management positions at Mobile TeleSystems (MTS), one of Russia’s largest telecommunications companies. At MTS Group he was Director of External Resource Management and Control, and in 2010 was appointed Head of Procurement and a member of the Management Board.

Previously Victor spent more than 10 years (1996-2006) developing ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding. Victor was promoted from Head of Treasury to Deputy CEO. His “portfolio” of professional experience includes participation in the foundation of the Institute of Design Automation of the USSR Academy of Sciences, where he was in charge of the laboratory of artificial intelligence systems in design automation.

Victor graduated from Moscow Aviation Institute as a radio engineer, and from the Russian Foreign Trade Academy, specialising in international economic relations. Victor acquired an additional degree in 2002 from the Financial University under the Government of the Russian Federation, specialising in economics and finance.

Media Center

  • 22 February 2018

    Korea pools patient data to enable digital health schemes

    South Korea is consolidating hospital medical data into a single 10 million-patient repository. The goal is to use Korea’s established medical IT system to build a resource that supports digital health initiatives and the development of new drugs and devices.

  • 21 February 2018

    Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

    Pfizer hasn't gained much market share with Inflectra, its biosimilar of Johnson & Johnson's Remicade, since its U.S. launch back in 2016. The company's CEO Ian Read recently said Inflectra is picking up increased commercial coverage, but an analyst figures the biosimilar's challenges aren't likely to let up this year. 

  • 20 February 2018

    Using stem cells to generate an immune attack against cancer

    Induced pluripotent stem cells (iPSCs) have the power to transform into any cell in the body, making them a prime candidate for regenerative medicine. But can they also teach the immune system to recognize and attack cancer?

  • 20 February 2018

    Russians develop advanced multiple myeloma drug candidate

    Hemopharm, a Russian biotech company, is developing a drug candidate that might help multiple myeloma patients. The new Hemopharm solution is expected to evolve to be such a drug. No direct competition has been reported so far in the global pharmaceutical market. The drug candidate is a humanized antibody with purportedly outstanding anti-tumor activity and low toxicity with proven in vivo efficacy.

Read more